Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)-Reference-Cited by-同舟云学术

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)

Published:2020-10-09 Issue:23 Volume:63 Page:14522-14529
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kanouni Toufike¹,Severin Christophe²,Cho Robert W.³,Yuen Natalie Y.-Y.⁴,Xu Jiangchun²,Shi Lihong²,Lai Chon²,Del Rosario Joselyn R.²,Stansfield Ryan K.⁵,Lawton Lee N.⁶,Hosfield David⁷,O’Connell Shawn⁸,Kreilein Matt M.⁹,Tavares-Greco Paula⁹,Nie Zhe¹⁰,Kaldor Stephen W.¹,Veal James M.⁵,Stafford Jeffrey A.⁵,Chen Young K.²^ORCID

Affiliation:

1. Fount Therapeutics, LLC, San Diego, California 92130, United States

2. Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, California 92121, United States

3. Quanticel Pharmaceuticels, San Francisco, California 94158, United States

4. Oric Pharmaceuticals, South San Francisco, California 94080, United States

5. 858 Therapeutics, Inc., San Diego, California 92121, United States

6. Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States

7. University of Chicago, Chicago, Illinois 60637, United States

8. Pfizer Inc., San Diego, California 92121, United States

9. Bristol Myers Squibb, Summit, New Jersey 07901, United States

10. Schrödinger, Inc., San Diego, California 92121, United States

Publisher